A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin Eudra CT2012-003984-23

Trial Profile

A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin Eudra CT2012-003984-23

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Therapeutic Use
  • Acronyms BOC-HIV
  • Most Recent Events

    • 08 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 May 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
    • 11 May 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2012-003984-23).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top